Synthesis, Biological Activity, ADME and Molecular Docking Studies of Novel Ursolic Acid Derivatives as Potent Anticancer Agents. 2023

Olga Michalak, and Marcin Cybulski, and Wojciech Szymanowski, and Agnieszka Gornowicz, and Marek Kubiszewski, and Kinga Ostrowska, and Piotr Krzeczyński, and Krzysztof Bielawski, and Bartosz Trzaskowski, and Anna Bielawska
Chemistry Section, Pharmacy, Cosmetic Chemistry and Biotechnology Research Group, Łukasiewicz Research Network-Industrial Chemistry Institute, 8 Rydygiera Str., 01-793 Warsaw, Poland.

A series of new ursolic acid (UA) derivatives substituted with various amino acids (AAs) or dipeptides (DP) at the C-3 position of the steroid skeleton was designed and synthesized. The compounds were obtained by the esterification of UA with the corresponding AAs. The cytotoxic activity of the synthesized conjugates was determined using the hormone-dependent breast cancer cell line MCF-7 and the triple-negative breast cancer cell line MDA. Three derivatives (l-seryloxy-, l-prolyloxy- and l-alanyl-l-isoleucyloxy-) showed micromolar IC50 values and reduced the concentrations of matrix metalloproteinases 2 and 9. Further studies revealed that for two compounds (l-seryloxy- and l-alanyl-l-isoleucyloxy-), a possible mechanism of their antiproliferative action is the activation of caspase-7 and the proapoptotic Bax protein in the apoptotic pathway. The third compound (l-prolyloxy- derivative) showed a different mechanism of action as it induced autophagy as measured by an increase in the concentrations of three autophagy markers: LC3A, LC3B, and beclin-1. This derivative also showed statistically significant inhibition of the proinflammatory cytokines TNF-α and IL-6. Finally, for all synthesized compounds, we computationally predicted their ADME properties as well as performed molecular docking to the estrogen receptor to assess their potential for further development as anticancer agents.

UI MeSH Term Description Entries
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D000097245 Ursolic Acid A pentacyclic triterpene that co-occurs with its isomer OLEANOLIC ACID in several plant species, and occurs in large amounts in FRUITS (such as CRANBERRIES; PEARS; PLUMS; and OLIVES), MEDICINAL HERBS, and other plants. (+)-Ursolic Acid,(3 beta)-3-Hydroxyurs-12-en-28-oic Acid,3-Epi-Ursolic Acid,3-Epiursolic Acid,3alpha-Ursolic Acid,3beta-Ursolic Acid,Olean-12-en-28-oic Acid, 3-Hydroxy-, Sodium Salt (1:1), (3beta)-,Sodium Oleanolate,Ursolic Acid Monosodium Salt,Ursolic Acid Sodium Salt,Ursolic Acid, (3beta)-Isomer, 2-(14)C-Labeled,Ursolic Acid, (3beta)-Isomer, Monopotassium Salt,Merotaine,3 Epi Ursolic Acid,3 Epiursolic Acid,3alpha Ursolic Acid,3beta Ursolic Acid,Oleanolate, Sodium
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Olga Michalak, and Marcin Cybulski, and Wojciech Szymanowski, and Agnieszka Gornowicz, and Marek Kubiszewski, and Kinga Ostrowska, and Piotr Krzeczyński, and Krzysztof Bielawski, and Bartosz Trzaskowski, and Anna Bielawska
November 2023, Archiv der Pharmazie,
Olga Michalak, and Marcin Cybulski, and Wojciech Szymanowski, and Agnieszka Gornowicz, and Marek Kubiszewski, and Kinga Ostrowska, and Piotr Krzeczyński, and Krzysztof Bielawski, and Bartosz Trzaskowski, and Anna Bielawska
January 2018, Chemical & pharmaceutical bulletin,
Olga Michalak, and Marcin Cybulski, and Wojciech Szymanowski, and Agnieszka Gornowicz, and Marek Kubiszewski, and Kinga Ostrowska, and Piotr Krzeczyński, and Krzysztof Bielawski, and Bartosz Trzaskowski, and Anna Bielawska
December 2015, Bioorganic chemistry,
Olga Michalak, and Marcin Cybulski, and Wojciech Szymanowski, and Agnieszka Gornowicz, and Marek Kubiszewski, and Kinga Ostrowska, and Piotr Krzeczyński, and Krzysztof Bielawski, and Bartosz Trzaskowski, and Anna Bielawska
September 2022, Molecules (Basel, Switzerland),
Olga Michalak, and Marcin Cybulski, and Wojciech Szymanowski, and Agnieszka Gornowicz, and Marek Kubiszewski, and Kinga Ostrowska, and Piotr Krzeczyński, and Krzysztof Bielawski, and Bartosz Trzaskowski, and Anna Bielawska
August 2023, Chemical biology & drug design,
Olga Michalak, and Marcin Cybulski, and Wojciech Szymanowski, and Agnieszka Gornowicz, and Marek Kubiszewski, and Kinga Ostrowska, and Piotr Krzeczyński, and Krzysztof Bielawski, and Bartosz Trzaskowski, and Anna Bielawska
April 2019, Bioorganic chemistry,
Olga Michalak, and Marcin Cybulski, and Wojciech Szymanowski, and Agnieszka Gornowicz, and Marek Kubiszewski, and Kinga Ostrowska, and Piotr Krzeczyński, and Krzysztof Bielawski, and Bartosz Trzaskowski, and Anna Bielawska
June 2021, Medical oncology (Northwood, London, England),
Olga Michalak, and Marcin Cybulski, and Wojciech Szymanowski, and Agnieszka Gornowicz, and Marek Kubiszewski, and Kinga Ostrowska, and Piotr Krzeczyński, and Krzysztof Bielawski, and Bartosz Trzaskowski, and Anna Bielawska
May 2012, Bioorganic & medicinal chemistry,
Olga Michalak, and Marcin Cybulski, and Wojciech Szymanowski, and Agnieszka Gornowicz, and Marek Kubiszewski, and Kinga Ostrowska, and Piotr Krzeczyński, and Krzysztof Bielawski, and Bartosz Trzaskowski, and Anna Bielawska
May 2016, Bioorganic & medicinal chemistry letters,
Olga Michalak, and Marcin Cybulski, and Wojciech Szymanowski, and Agnieszka Gornowicz, and Marek Kubiszewski, and Kinga Ostrowska, and Piotr Krzeczyński, and Krzysztof Bielawski, and Bartosz Trzaskowski, and Anna Bielawska
April 2021, International journal of molecular sciences,
Copied contents to your clipboard!